Thermo Fisher joins PRECISE SG100K biobank initiative in Singapore
Thermo Fisher Scientific entered a collaboration with Singapore's PRECISE to support the PRECISE SG100K biobank initiative. The company will supply proteomics capabilities for precision medicine research and biomarker discovery in Asia Pacific.
Thermo Fisher Scientific has entered a collaboration with Singapore's PRECISE to support the large scale PRECISE SG100K biobank initiative. The company is supplying integrated multi platform proteomics capabilities, including Olink PEA and Orbitrap Astral mass spectrometry, alongside partners such as Seer and Novogene.
The alliance is intended to support population scale precision medicine research and biomarker discovery across the Asia Pacific region. The project focuses on regulatory grade research and the scale of biological data involved in large biobank and clinical research environments.
The collaboration positions Thermo Fisher's proteomics platforms in areas such as clinical proteomics, biomarker validation, and long term partnerships with public research programs. For investors tracking NYSE:TMO, the stock was trading at $496.11.
Recent performance was mixed, with a 6.8% return over 30 days, 13.6% over 1 year, a 16.3% decline year to date, and a 15.0% decline over 3 years.